| Abstract P163 – Table 1. Baseline characteristics of 357 experienced patients in the study. | |||
|---|---|---|---|
| Variables at enrolment | 2DR N = 104 mean SD or N (%) or median (IQR) | TAF‐BR N = 253 mean SD or N (%) or median (IQR) | p |
| Age, years | 48.5±13.2 | 48.4±11.5 | 0.96 |
| Sex, M | 80 (76.9%) | 187 (73.9%) | 0.55 |
| BMI, kg/m2 | 25.4±3.9 | 26.0±6.0 | 0.35 |
| Weight, kg | 75.8±13.7 | 75.2±14.3 | 0.74 |
| Caucasian | 94 (90.4%) | 219 (86.6%) | 0.32 |
| Risk factor for HIV acquisition | |||
| Sexual | 95 (91.4%) | 174 (68.8%) | − |
| IDU | 6 (5.6%) | 40 (15.8%) | − |
| Other/ND | 3 (2.9%) | 39 (15.4%) | <0.0001 |
| HCV coinfection (n = 107/329) | 7 (6.9%) | 55 (23.2%) | 0.0004 |
| Previous ART | |||
| PI | 7 (6.7%) | 38 (15.0%) | 0.03 |
| INSTI | 56 (53.8%) | 191 (75.5%) | <0.0001 |
| NNRTI | 36 (34.6%) | 14 (5.5%) | <0.0001 |
| COBI‐including regimens | 37 (35.6%) | 161 (63.6%) | <0.0001 |
| CDC stage | |||
| A | 80 (76.9%) | 129 (51.2%) | − |
| B | 19 (18.3%) | 78 (31.0%) | − |
| C | 5 (4.8%) | 45 (17.9%) | <0.0001 |
| CD4, cells/mm3 | 738 (614 to 926) | 645 (490 to 838) | 0.0002 |
| Total cholesterol, mg/dL | 197±37 | 196±41 | 0.91 |
| HDL‐cholesterol, mg/dL | 51±14 | 52±17 | 0.45 |
| LDL‐cholesterol, mg/dL | 119±32 | 116±36 | 0.35 |
| Triglycerides, mg/dL | 108 (80 to 154) | 115 (85 to 163) | 0.33 |
| Blood glucose, mg/dL (nondiabetics) | 88±12 | 93±15 | 0.004 |
| Blood glucose, mg/dL (diabetics) | 117±40 | 163±69 | 0.17 |
| On lipid‐lowering drugs | 8 (7.7%) | 42 (16.6%) | 0.03 |
| AST, IU/dL | 21 (17 to 25) | 21 (18 to 26) | 0.23 |
| ALT, IU/dL | 21 (16 to 27) | 21 (16 to 29) | 0.44 |
2DR, two‐drug regimen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CDC, Centers for Disease Control and Prevention; COBI, cobicistat; HCV, hepatitis C virus; HDL, high density lipoprotein; IDU, intravenous drug user; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; IU, international unit; LDL, low density lipoprotein; M, male; ND, not determined; NNRTI, non‐nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SD, standard deviation; TAF‐BR, tenofovir alafenamide‐based regimen.